Commodore Capital LP Macrogenics Inc Transaction History

Commodore Capital LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$9.77 - $21.47 $2.88 Million - $6.33 Million	295,020 New	295,020 $4.34 Million
Q3 2021 Nov 15, 2021	SELL	$19.74 - $28.7 $7.77 Million - $11.3 Million	-393,850 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$20.49 - $35.63 $7.11 Million - $12.4 Million	347,220 Added 744.63%	393,850 $10.6 Million
Q1 2021 May 17, 2021	BUY	$18.99 - $33.2 $885,503 - $1.55 Million	46,630 New	46,630 $1.49 Million

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $200M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Commodore Capital LP, based on Form 13F filings with the SEC.

Stay updated on Commodore Capital LP with notifications on news.